FDA Advisers Review Galleri Multicancer Test as Medicare Coverage Looms

FDA advisory panel reviews Galleri multicancer test

The Food and Drug Administration has convened an advisory committee to examine the clinical data behind Grail's Galleri test, a blood based assay that claims to detect signals from more than fifty cancer types. The panel will assess whether the test meets the agency's standards for safety, accuracy, and clinical utility before any formal regulatory decision is made.

Background on the Galleri test

Galleri was launched in 2021 after early studies suggested it could identify cancer DNA fragments in a routine blood draw. The test uses next generation sequencing and machine learning algorithms to differentiate tumor‑derived DNA from normal cell DNA. Grail markets the assay as a potential tool for population level screening, positioning it alongside traditional imaging methods such as mammography and colonoscopy.

Key findings of the recent trial

A large prospective study involving more than 140,000 participants was published in a peer reviewed journal last year. The trial reported a sensitivity of roughly 40 percent for stage I cancers, but the overall ability to detect later stage disease was lower than initially hoped. Importantly, the study did not demonstrate a clear reduction in cancer mortality, a benchmark that regulators typically require for screening approvals.

• Detection rate for stage I disease: about 40 percent.
• Detection rate for stage II‑IV disease: varied widely by cancer type.
• No statistically significant impact on overall survival was observed.
• False positive rate led to additional diagnostic procedures for a small subset of participants.

The trial's limitations have become a focal point of the advisory meeting. Critics argue that the heterogeneous performance across cancer sites makes it difficult to justify universal screening, while supporters point to the test's ability to find cancers that are not routinely screened.

Implications for Medicare coverage

Medicare, the federal health insurance program for seniors, has a separate process for deciding whether to reimburse new diagnostic technologies. Coverage decisions often rely on evidence that a test improves health outcomes and is cost effective.

Coverage criteria under Medicare

To qualify for reimbursement, a screening test typically must:

1. Demonstrate a reduction in disease‑specific mortality.
2. Show that the benefits outweigh the harms of false positives.
3. Provide evidence of cost effectiveness compared with existing standards of care.

Grail has submitted a coverage request that references the same large trial evaluated by the FDA panel. The request also includes modeling data that predicts long term savings from earlier cancer detection, but those projections have not yet been independently verified.

Potential impact on patients and providers

If Medicare were to cover Galleri, millions of beneficiaries could gain access to a blood test that screens for many cancers in a single visit. Primary care physicians would need guidance on how to interpret positive results and when to refer patients for confirmatory imaging or biopsy.

Conversely, a decision not to cover the test could limit its adoption to private insurers and self‑pay patients, potentially widening health disparities. The outcome of the advisory panel will likely influence the Medicare deliberations, as both agencies often coordinate their assessments of new medical technologies.

Industry response and next steps

Grail has expressed confidence that additional data will address the concerns raised by regulators. The company announced plans to launch a follow‑up study that will enroll participants with higher risk factors, such as a strong family history of cancer.

Grail’s plan for further data

The upcoming trial aims to:

• Enrich the study population for cancers that are currently detected with lower sensitivity.
• Collect long term outcome data to evaluate mortality impact.
• Assess the economic implications of widespread screening.

Results are expected within the next two years, and Grail hopes that the new evidence will satisfy both the FDA advisory committee and Medicare policymakers.

Broader market for blood based cancer screening

Galleri is not the only blood test seeking regulatory clearance. Several companies are developing assays that target specific cancer signatures, and the FDA has recently cleared a test for early detection of colorectal cancer based on stool DNA. The competitive landscape suggests that the agency is moving toward a more nuanced framework for evaluating multicancer screening technologies.

Stakeholders across the healthcare system are watching the FDA panel closely. A positive recommendation could set a precedent that encourages further investment in blood based screening, while a negative outcome may prompt companies to refine their technologies before seeking approval.

Regardless of the final decision, the conversation around multicancer detection highlights the tension between innovation and evidence. Patients, providers, and payers will continue to weigh the promise of early detection against the need for robust data that proves real health benefits.